IRNA agents targeting VEGF

Details IRNA agents targeting VEGF IRNA agents targeting VEGF

2011-04-05

2011-04-05

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500

Reexamination Certificate

active

07919473

ABSTRACT:
The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

REFERENCES:
patent: 4426330 (1984-01-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4837028 (1989-06-01), Allen
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5627053 (1997-05-01), Usman et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5716824 (1998-02-01), Beigelman et al.
patent: 5854038 (1998-12-01), Sullenger et al.
patent: 5902880 (1999-05-01), Thompson
patent: 6054299 (2000-04-01), Conrad
patent: 6146886 (2000-11-01), Thompson
patent: 6150092 (2000-11-01), Uchida et al.
patent: 6395713 (2002-05-01), Beigelman et al.
patent: 2003/0203844 (2003-10-01), Delfani et al.
patent: 2004/0018176 (2004-01-01), Tolentino et al.
patent: 2004/0180847 (2004-09-01), Dobie et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2005/0255487 (2005-11-01), Khvorova et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 10100586 (2002-04-01), None
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/15187 (1993-08-01), None
patent: WO 93/23569 (1993-11-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 94/02595 (1994-02-01), None
patent: WO 94/13788 (1994-06-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/13526 (1998-04-01), None
patent: WO 99/61631 (1999-02-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/53722 (2000-09-01), None
patent: WO 03/070910 (2003-08-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 2004/001193 (2003-12-01), None
patent: WO 2004/007070 (2004-01-01), None
patent: WO 2004/011829 (2004-02-01), None
patent: WO 2004/011822 (2004-05-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2004/094595 (2004-11-01), None
patent: WO 2004/099410 (2004-11-01), None
patent: WO 2005/014782 (2005-02-01), None
Vickers et al. (2003) J. Biol. Chem. 278:7108-7118.
Elbashir et al. (2001) Nature 411:494-498.
Bass (2001) Nature 411:428-9.
Fattal et al. (2006) Advanced Drug Delivery Reviews 58:1203-1223.
Holen et al. (2002) Nucleic Acids Res. 8:1757-1766.
Akhtar et al, “Cellular uptake and intracellular fate of antisense oligonucleotides”Trends Cell Biol. 2:139-144(1992).
Aldrian-Herrada et al., “A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to aretro-inversodelivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons”Nucleic Acids Res. 26:4910-4916 (1998).
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes”J. Biol. Chem. 270:25702-25708 (1995).
Bernstein et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”Nature409:363-366 (2001).
Boado, “Antisense drug delivery through the blood-brain barrier”Adv. Drug. Deliv. Rev. 15:73-107 (1995).
Boado et al., “Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS”J. Pharm. Sci. 87:1308-1315 (1998).
Burgin, Jr. et al., “Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates”Biochemistry35:14090-14097 (1996).
Burlina et al., “Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes”Bioorg. Med. Chem. 5:1999-2010 (1997).
Chen et al., “Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication—potential effectiveness against most presently sequenced HIV-1 isolates”Nucleic Acids Res. 20:4581-4589 (1992).
Chowrira et al., “In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes”J. Biol. Chem. 269:25856-25864 (1994).
Couture et al., “Anti-gene therapy: the use of ribozymes to inhibit gene function”Trends Genet. 12:510-515 (1996).
Dropulić et al., “Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type 1 Expression”J. Virol. 66:1432-1441 (1992).
Dunn et al., “ARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties”Exp. Eye Res. 62:155-169 (1996).
Earnshaw et al., “Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function”Biopolymers48:39-55 (1998).
Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”Nature411:494-498 (2001).
Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”Genes Dev. 15:188-200 (2001).
Filleur et al., “SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth”Cancer Res. 63:3919-3922 (2003).
Fire et al., “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans” Nature391:806-811 (1998).
GenBank Accession No. AF214570, “Homo sapiensvascular endothelial growth factor isoform 121 precursor, mRNA, complete cds” Dec. 23, 1999.
Gonzalez et al., “New Class of Polymers for the Delivery of Macromolecular Therapeutics”Bioconjug. Chem. 10:1068-1074 (1999).
Good et al., “Expression of small, therapeutic RNAs in human cell nuclei”Gene Ther. 4:45-54 (1997).
Hofland et al., “Chapter 8: Formulation and Delivery of Nucleic Acids”Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing, Edited by Dale L. Oxender and Leonard E. Post, Springer-Verlag Berlin Heidelberg, pp. 165-192 (1999).
Ishiwata et al, “Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether”Chem. Pharm. Bull.(Tokyo) 43:1005-1011 (1995).
Izant et al., “Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA”Science229:345-352 (1985).
Jolliet-Riant et al., “Drug transfer across the blood-brain barrier and improvement of brain delivery”Fundam. Clin. Pharmacol. 13:16-26 (1999).
Karpeisky et al., “Highly Efficient Synthesis of 2′-O-Amino Nucleosides And Their Incorporation In Hammerhead Ribozymes”Tetrahedron Lett. 39:1131-1134 (1998).
Kashani-Sabet et al., “Reversal of the Malignant Phenotype by an Anti-rasRibozyme”Antisense Res. Dev. 2:3-15 (1992).
Kawasaki et al., “Uniformly Modified 2′-Deoxy-2′-fluoro Phosphoro

Affiliated with

Also associated with

Rating

IRNA agents targeting VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IRNA agents targeting VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IRNA agents targeting VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2691174